173 related articles for article (PubMed ID: 21463600)
1. Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities.
Gautam AH; Zeevalk GD
Biochim Biophys Acta; 2011 Jul; 1807(7):819-28. PubMed ID: 21463600
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson's disease.
Nunes C; Almeida L; Laranjinha J
Neurochem Int; 2005 Aug; 47(3):173-82. PubMed ID: 15893407
[TBL] [Abstract][Full Text] [Related]
3. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
Jana S; Maiti AK; Bagh MB; Banerjee K; Das A; Roy A; Chakrabarti S
Brain Res; 2007 Mar; 1139():195-200. PubMed ID: 17291463
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
Khan FH; Sen T; Maiti AK; Jana S; Chatterjee U; Chakrabarti S
Biochim Biophys Acta; 2005 Jun; 1741(1-2):65-74. PubMed ID: 15925494
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.
Fornstedt Wallin B
J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Gluck MR; Zeevalk GD
J Neurochem; 2004 Nov; 91(4):788-95. PubMed ID: 15525332
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides.
Gluck M; Ehrhart J; Jayatilleke E; Zeevalk GD
J Neurochem; 2002 Jul; 82(1):66-74. PubMed ID: 12091466
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis.
Nunes C; Barbosa RM; Almeida L; Laranjinha J
Mol Cell Neurosci; 2011 Sep; 48(1):94-103. PubMed ID: 21708261
[TBL] [Abstract][Full Text] [Related]
9. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
11. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease.
Li H; Shen XM; Dryhurst G
J Neurochem; 1998 Nov; 71(5):2049-62. PubMed ID: 9798930
[TBL] [Abstract][Full Text] [Related]
12. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B
J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937
[TBL] [Abstract][Full Text] [Related]
13. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
[TBL] [Abstract][Full Text] [Related]
14. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio.
Titov DV; Cracan V; Goodman RP; Peng J; Grabarek Z; Mootha VK
Science; 2016 Apr; 352(6282):231-5. PubMed ID: 27124460
[TBL] [Abstract][Full Text] [Related]
15. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain.
Karoum F; Chrapusta SJ; Brinjak R; Hitri A; Wyatt RJ
Br J Pharmacol; 1994 Dec; 113(4):1391-9. PubMed ID: 7889297
[TBL] [Abstract][Full Text] [Related]
16. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
Shen XM; Dryhurst G
Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
[TBL] [Abstract][Full Text] [Related]
17. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
[TBL] [Abstract][Full Text] [Related]
18. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
[TBL] [Abstract][Full Text] [Related]
19. Dopamine oxidation products inhibit Na+, K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain.
Khan FH; Sen T; Chakrabarti S
Free Radic Res; 2003 Jun; 37(6):597-601. PubMed ID: 12868486
[TBL] [Abstract][Full Text] [Related]
20. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
Shen XM; Li H; Dryhurst G
J Neural Transm (Vienna); 2000; 107(8-9):959-78. PubMed ID: 11041275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
